Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 174

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience

Open access
Chamoun, Kamal, Kantarjian, Hagop, Atallah, Rami, Gonzalez, Graciela Nogueras, Issa, Ghayas C., Rios, Mary Beth, Garcia-Manero, Guillermo, Borthakur, Gautam, Ravandi, Farhad, Jain, Nitin, Daver, Naval, Konopleva, Marina, DiNardo, Courtney D., Kadia, Tapan, Pemmaraju, Naveen, Jabbour, Elias, Cortes, Jorge · 2019 · Journal of Hematology & Oncology

Abstract

Patients with CML treated with TKI can have a life expectancy comparable to that of the general population. Due to the extended duration of TKI administration, treatment discontinuation has been increasingly sought. Medical records of 100 patients with CML who were in MR 4.5 and discontinued their TKI outside clinical trials were reviewed. After a median follow-up of 30 months (range, 5–112 months) after discontinuation, 35% and 17% lost MR 4.5 and major molecular response (MMR), respectively. Only six patients lost MMR 12 months or more after discontinuation. Loss of MR 4.5 was observed in 29% and 7% of patients with sustained MR 4.5 duration of more than 2 and 6 years before discontinuation, respectively. By univariate analysis, there was a higher risk of loss of MR 4.5 for patients who were treated for less than 87 months, received second or subsequent line TKI, never received interferon, or those with sustained MR 4.5 for less than 6 years. By multivariate analysis, sustained MR 4.5 for 6 years or more was the only significant predictor for durable response. Overall, 30% of patients who discontinued while in MR 4.5 were retreated with 93% regaining MR 4.5 at a median of 5 months. These results demonstrate that under proper conditions, treatment discontinuation is feasible outside of clinical trial setting. MR 4.5 duration of 6 years or more before discontinuation is associated with very low risk of loss of MR 4.5 .

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13045-018-0686-1

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 31

  1. O’Brien SG, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994–1004. · DOI · Paper page
  2. Kantarjian H, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood. 2012;119(9):1981–7. · DOI · Paper page
  3. Cortes JE, et al. Bosutinib (BOS) versus imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): initial results from the BFORE trial. J Clin Oncol. 2017;35:7002. · doi:10.1200/jco.2017.35.15_suppl.7002
  4. Cortes JE, et al. Final 5-year study results of DASISION: the Dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333–U54. · DOI · Paper page
  5. Hochhaus A, et al. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. Leukemia. 2016;30(1):57–64. · DOI
  6. Benjamini O, et al. Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience. Leuk Lymphoma. 2014;55(12):2879–86. · DOI
  7. Falchi L, et al. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol. 2013;88(12):1024–9. · DOI
  8. Doggrell SA, Christensen AM. Are there better Bcr-Abl kinase inhibitors for chronic myeloid leukaemia than imatinib? Evaluation of Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251–9, and Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260–70. Expert Opin Pharmacother. 2011;12(1):157–63. · DOI
  9. Baccarani M, et al. A review of the European LeukemiaNet recommendations for the management of CML. Ann Hematol. 2015;94:S141–7. · DOI · Paper page
  10. Dusetzina SB, et al. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol. 2014;32(4):306–11. · DOI · Paper page
  11. Douxfils J, et al. Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival a systematic review and meta-analysis. Jama Oncology. 2016;2(5):625–32. · DOI · Paper page
  12. Ault P, et al. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol. 2006;24(7):1204–8. · DOI · Paper page
  13. Pye SM, et al. The effects of imatinib on pregnancy outcome. Blood. 2008;111(12):5505–8. · DOI · Paper page
  14. Cortes JE, et al. The impact of dasatinib on pregnancy outcomes. Am J Hematol. 2015;90(12):1111–5. · DOI
  15. Mahon FX, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029–35. · DOI · Paper page
  16. Ross DM, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122(4):515–22. · DOI · Paper page
  17. Mahon FX, et al. Interim analysis of a Pan European stop tyrosine kinase inhibitor trial in chronic myeloid leukemia : the EURO-SKI study. Blood. 2014;124(21):151. · DOI
  18. Rea D, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood. 2017;129(7):846–54. · DOI · Paper page
  19. Hochhaus A, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017;31(7):1525–31. · DOI · Paper page
  20. Imagawa J, et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol. 2015;2(12):e528–35. · DOI · Paper page
  21. Tanaka C, et al. GADD34 suppresses wound healing by upregulating expression of myosin IIA. Transgenic Res. 2010;19(4):637–45. · doi:10.1007/s11248-009-9347-z
  22. Isobe N, Hosoda K, Yoshimura Y. Immunolocalization of lingual antimicrobial peptide (LAP) in the bovine mammary gland. Anim Sci J. 2009;80(4):446–50. · doi:10.1111/j.1740-0929.2009.00652.x
  23. Goda A, et al. Heart failure with preserved versus reduced left ventricular systolic function: a prospective cohort of Shinken Database 2004-2005. J Cardiol. 2010;55(1):108–16. · doi:10.1016/j.jjcc.2009.10.009
  24. Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. Blood. 2016;128(1):17–23. · DOI · Paper page
  25. Baccarani M, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27(35):6041–51. · DOI · Paper page
  26. Hughes TP, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of interferon and STI571 (IRIS). Blood. 2010;116(19):3758–65. · DOI · Paper page
  27. Gunnarsson N, et al. Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era. Br J Haematol. 2015;169(5):683–8. · DOI
  28. Gugliotta G, et al. Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia. Haematologica. 2017;102(9):1530–6. · doi:10.3324/haematol.2017.169532
  29. Verma D, et al. Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood. 2011;118(16):4353–8. · doi:10.1182/blood-2011-06-362889
  30. Goldman JM, et al. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. J Clin Oncol. 2010;28(11):1888–95. · DOI
  31. Etienne G, et al. Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol. 2017;35(3):298. · DOI · Paper page

Cited by

See all 174

Metadata

Authors
Chamoun, K., Kantarjian, H., Atallah, R., Gonzalez, G. N., Issa, G. C., Rios, M. B., Garcia-Manero, G., Borthakur, G., Ravandi, F., Jain, N., Daver, N., Konopleva, M., DiNardo, C. D., Kadia, T., Pemmaraju, N., Jabbour, E., & Cortes, J.
Venue
Journal of Hematology & Oncology
Published
2019-01-03
Volume
12
Issue
1
Pages
1-1
ISSN
1756-8722 (ISSN-L)
OpenAlex
W2913116303
Cited by
174
References
1
FWCI
14.35
Type
journal article
Language
en
Open access
gold
Licence
creativecommons.org/licenses/by/4.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. https://app.cochat.ai/papers/10.1186/s13045-018-0686-1
The paper
Chamoun, K., Kantarjian, H., Atallah, R., Gonzalez, G. N., Issa, G. C., Rios, M. B., Garcia-Manero, G., Borthakur, G., Ravandi, F., Jain, N., Daver, N., Konopleva, M., DiNardo, C. D., Kadia, T., Pemmaraju, N., Jabbour, E., & Cortes, J. (2019). Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. Journal of Hematology & Oncology. https://doi.org/10.1186/s13045-018-0686-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.